Axa decreased its position in TESARO, Inc. (NASDAQ:TSRO) by 6.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,149 shares of the biopharmaceutical company’s stock after selling 4,437 shares during the quarter. Axa owned approximately 0.12% of TESARO worth $8,972,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Botty Investors LLC bought a new position in shares of TESARO in the second quarter valued at approximately $140,000. Meeder Asset Management Inc. bought a new position in shares of TESARO in the first quarter valued at approximately $177,000. Oppenheimer Asset Management Inc. raised its position in shares of TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,430 shares during the period. BB&T Securities LLC bought a new position in shares of TESARO in the second quarter valued at approximately $222,000. Finally, Fox Run Management L.L.C. bought a new position in shares of TESARO in the second quarter valued at approximately $224,000.

In other TESARO news, VP Grant C. Bogle sold 14,167 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Edward C. English sold 10,862 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the completion of the transaction, the vice president now directly owns 6,258 shares in the company, valued at $844,329.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,100 shares of company stock worth $3,387,465. Insiders own 34.60% of the company’s stock.

Shares of TESARO, Inc. (TSRO) opened at 118.22 on Wednesday. TESARO, Inc. has a 1-year low of $91.76 and a 1-year high of $192.94. The firm’s market cap is $6.41 billion. The firm’s 50-day moving average is $123.15 and its 200-day moving average is $141.79.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same period in the prior year, the company earned ($1.28) earnings per share. The business’s quarterly revenue was down 17.6% compared to the same quarter last year. On average, analysts anticipate that TESARO, Inc. will post ($8.67) EPS for the current fiscal year.

A number of research firms have recently commented on TSRO. Cowen and Company set a $145.00 price target on shares of TESARO and gave the company a “hold” rating in a research report on Saturday, June 10th. Janney Montgomery Scott set a $139.00 price target on shares of TESARO and gave the company a “hold” rating in a research report on Saturday, June 10th. Credit Suisse Group set a $190.00 price target on shares of TESARO and gave the company a “buy” rating in a research report on Friday, August 18th. Robert W. Baird reissued a “neutral” rating on shares of TESARO in a research report on Tuesday, June 6th. Finally, FBR & Co dropped their price target on shares of TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a research report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $175.15.

COPYRIGHT VIOLATION WARNING: “TESARO, Inc. (TSRO) Stake Lowered by Axa” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/09/13/tesaro-inc-tsro-stake-lowered-by-axa.html.

TESARO Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.